Ming-Neng Shiu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 13

Top Topics

Randomized Controlled Trial

Top Venues

Journal of the American Heart Association

PharmacoEconomics

BMC public health

This page only lists publications with an associated author ORCID identifier.

Publications

Wei-Lun Chang, Ying-Fan Chen, Yu-Hsuan Lee, Ming-Neng Shiu, Po-Yin Chang, Chao-Yu Guo, Chi-Jung Huang, Chern-En Chiang, Chen-Huan Chen, Shao-Yuan Chuang, Babangida S Chori
Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure. Journal of the American Heart Association (2024)
Chen-Han Chueh, Pei-Kuan Ho, Wai-Hou Li, Ming-Neng Shiu, I-Ting Wang, Yu-Wen Wen, Yi-Wen Tsai
The 2017 Women's Health Initiative study and use of hormone therapy: an emulated repeated cross-sectional study. BMC public health 24 (1) (2024)
Wei-Lun Chang, Ying-Fan Chen, Yu-Hsuan Lee, Ming-Neng Shiu, Po-Yin Chang, Chao-Yu Guo, Chi-Jung Huang, Chern-En Chiang, Chen-Huan Chen, Shao-Yuan Chuang, Babangida S Chori
Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure. Journal of the American Heart Association 13 (8) (2024)
Wei-Lun Chang, Ying-Fan Chen, Yu-Hsuan Lee, Ming-Neng Shiu, Po-Yin Chang, Chao-Yu Guo, Chi-Jung Huang, Chern-En Chiang, Chen-Huan Chen, Shao-Yuan Chuang, Babangida S Chori
Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure. Journal of the American Heart Association 13 (8) (2024)
Chen-Han Chueh, Pei-Kuan Ho, Wai-Hou Li, Ming-Neng Shiu, I-Ting Wang, Yu-Wen Wen, Yi-Wen Tsai
The 2017 Women's Health Initiative study and use of hormone therapy: an emulated repeated cross-sectional study. BMC public health 24 (1) (2024)
Wei-Lun Chang, Ying-Fan Chen, Yu-Hsuan Lee, Ming-Neng Shiu, Po-Yin Chang, Chao-Yu Guo, Chi-Jung Huang, Chern-En Chiang, Chen-Huan Chen, Shao-Yuan Chuang, Babangida S Chori
Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure. Journal of the American Heart Association 13 (8) (2024)
Wei-Lun Chang, Ying-Fan Chen, Yu-Hsuan Lee, Ming-Neng Shiu, Po-Yin Chang, Chao-Yu Guo, Chi-Jung Huang, Chern-En Chiang, Chen-Huan Chen, Shao-Yuan Chuang, Babangida S Chori
Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure. Journal of the American Heart Association 13 (8) (2024)
Wei-Lun Chang, Ying-Fan Chen, Yu-Hsuan Lee, Ming-Neng Shiu, Po-Yin Chang, Chao-Yu Guo, Chi-Jung Huang, Chern-En Chiang, Chen-Huan Chen, Shao-Yuan Chuang, Babangida S Chori
Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure. Journal of the American Heart Association 13 (8) (2024)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)